horizon grammatica icon icon map search arrow rss twitter facebook apply twitter facebook rss

Nearmedic Pharma — production of Kagocel medicine, innovative substances’ synthesis, collagen processing

September 2010
agreement on construction of a pharmaceutical plant between the government of Kaluga region and the Russian pharmaceutical company was signed
June 2015
an official ceremony dedicated to commissioning of Nearmedic pharmaceutical production facility was held in Obninsk industrial park.
May 2016
National Center for Labor Glory, Vremya Rossii (Time of Russia) online media and Vremya Rossii almanac announced the Event of the Year. Russia 2015 Web polling results. Nearmedic Pharma plant located in Kaluga Region was the winner in Pharmaceutical Industry category.
November 2018
First Russian production facility to manufacture reactants for genetic person’s identification and establishment of filiation

The plant meets all GMP, ISO and FDA requirements.

It has an area of 22,000 sq.m. This is a unique production facility as it boasts an entire production cycle from source substances’ synthesis to production of finished products. The entire range of products was developed by the company itself. The company supplies a number of vital pharmaceuticals to the Russian market, including Kagocel ®, anti-virus interferon inducing agent, actively used for treatment of flu and ARVI. According to IMS Health, in 2014 Kagocel held the first place in the market in terms of packed anti-virus pharmaceuticals sales with a share of 23.26%. Another plant product, KOLLOST ®, is a regenerating collagen complex widely used in surgery, dentistry and cosmetology.

Scope of investments: RUR 4 billion. Plant production capacity: up to 100 million packs per annum. Personnel: 185.  

Vladimir Nesterenko, Director General, Nearmedic Plus OOO, said:
“Nearmedic portfolio consists of about 20 products we plan to manufacture at Kaluga Region plant. This is to make Russia less dependent on imported medicines. Apart from that we are engaged in a research project to create a drug combating tuberculosis in cooperation with a Swiss university. The project is of great social importance. The new pharmaceutical is to be manufactured here. It will be distributed in Russia and the CIS countries. We will also be able to export it, if necessary”. (05.06.2015)

Denis Manturov, Minister for Industry and Trade of the Russian Federation, said:
“It is absolutely clear why such a plant was built in Obninsk, the first Russian science city. Construction of such a large-scale production facility in Obninsk is to become another incentive for other companies operating in Kaluga Region and Russia to create innovative plants. DNA tests is an area being currently developed by Nearmedic. The Foundation for Industry Development under the Ministry of Industry and Trade is to be one of the sponsors of the project. The project is of great importance as the share of imported products used in this area equals 98%. When the plant reaches its full capacity we will be able to substitute virtually all imported products”. (05.06.2015)

About Nearmedic GK

The company was established by likeminded scientists from N.F.Gamaleya Epidemiology and Microbiology Science and Research Institute to introduce the results of their researches and developments in various areas of laboratory diagnostics, immunology, infectology, etc.

Nearmedic GK celebrates its 26th anniversary in 2015. Professor Vladimir G. Nesterenko, DSc., a prominent Russian immunologist, was among the company’s founders. He also heads the company from the day of its inception. He joined N.F.Gamaleya Epidemiology and Microbiology Science and Research Institute when he was a post-graduate student. After defending his PhD thesis he rose through the ranks from junior research associate to the member of the Scientific Council (1984), the head of immune response regulation laboratory (1985) and the head of immunology department (1986).  Vladimir G. Nesterenko has been the head of Nearmedic since 1989.

Initially the company was engaged in development of diagnostics business. Development of modern production facilities meeting GMP requirements, wide introduction of modern diagnostics test systems for laboratories diagnosing major infectious diseases, including STIs, HIV, virus hepatitis, TORCH infections, etc., was the foundation of the company’s success.